NCT02594566View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine

PHASE1WithdrawnINTERVENTIONAL

Timeline

Start Date

November 30, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

February 28, 2017

Conditions

Congenital Cytomegalovirus Infection

Interventions

DRUG

CyMVectin

CyMVectin will be delivered by unilateral intramuscular (IM) injection at Day 0, Day 28(+4 days), and Day 56 (+4 days) in alternating arms. Each dose of CyMVectin will be administered in a 1.0-mL volume